GlassScriptPhysician profile
Yunhee Chung
NPI 1205948668
$61,458.16
in general payments reported to CMS, 2019-2025
75 companies · $4,073 in 2025
The $4,073 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $9,914 · 2021: $10K · 2022: $6,894 · 2023: $7,389 · 2024: $7,119 · 2025: $4,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $884 · Long Term Medical Supply Or Device Loan: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,032.71 |
| Education | $883.63 |
| Long Term Medical Supply Or Device Loan | $665.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17,302.51 | 2019-2025 | Evenity, Prolia, Repatha |
| Eisai INC. | $6,339.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,829.13 | 2019-2025 | Tagrisso, Calquence, Farxiga |
| Astellas Pharma US INC | $1,967.63 | 2019-2024 | Xtandi, Padcev, Xospata |
| Incyte Corporation | $1,861.23 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,777.23 | 2019-2025 | Jardiance, Gilotrif |
| Celgene Corporation | $1,774.23 | 2019-2024 | Pomalyst, Reblozyl |
| Pfizer INC. | $1,541.61 | 2019-2025 | |
| Janssen Biotech, INC. | $1,535.78 | 2019-2025 | Erleada, Akeega, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $1,480.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,342.01 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $1,325.02 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $1,314.14 | 2019-2025 | Viberzi, Linzess, Creon |
| Lilly USA, LLC | $1,292.64 | 2019-2024 | Jaypirca, Verzenio, Mounjaro |
| Exelixis INC. | $1,197.36 | 2021-2024 | Cabometyx |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $1,087.52 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $1,058.73 | 2019-2025 | Vemlidy |
| E.R. Squibb & Sons, L.L.C. | $1,033.25 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Amarin Pharma, INC. | $1,022.89 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $935.27 | 2023-2025 | Orgovyx, Gemtesa |
| Puma Biotechnology, INC. | $932.64 | 2019-2025 | Nerlynx |
| Novo Nordisk INC | $846.62 | 2019-2025 | Ozempic, Rybelsus |
| Seagen INC. | $828.08 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Nestle Healthcare Nutrition INC. | $589.92 | 2020-2023 | |
| Glaxosmithkline, LLC. | $478.56 | 2019-2025 | Zejula, Jemperli, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $439.98 | 2024-2025 | Voquezna |
| Array Biopharma INC | $436.78 | 2020-2024 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $430.10 | 2019-2023 | Tecentriq |
| Genzyme Corporation | $408.03 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $386.94 | 2019-2022 | |
| Allergan, INC. | $383.61 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $378.39 | 2020-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $368.00 | 2022-2025 | |
| Myovant Sciences INC. | $363.39 | 2021-2022 | |
| Emd Serono, INC. | $324.39 | 2019-2023 | Bavencio |
| Daiichi Sankyo INC. | $270.29 | 2023-2024 | Enhertu |
| Mirati Therapeutics, INC. | $249.79 | 2023-2024 | Krazati |
| Dova Pharmaceuticals | $215.87 | 2020-2021 | |
| Deciphera Pharmaceuticals INC. | $207.84 | 2021-2024 | Qinlock |
| Aimmune Therapeutics, INC. | $189.58 | 2024-2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $189.42 | 2024-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $179.40 | 2022-2023 | Fotivda |
| Jazz Pharmaceuticals INC. | $169.25 | 2020-2021 | |
| Tesaro, INC. | $160.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $159.65 | 2021-2024 | Xarelto |
| Clovis Oncology, INC. | $151.92 | 2019-2022 | |
| Exact Sciences Corporation | $141.58 | 2025 | Cologuard Collection Kit |
| Foundation Medicine, INC. | $128.46 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $117.37 | 2019-2021 | |
| Beigene USA, INC. | $107.85 | 2023-2024 | Brukinsa |
| Global Blood Therapeutics, INC. | $106.93 | 2020-2021 | |
| Pharmaessentia USA Corporation | $101.31 | 2023-2024 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $93.49 | 2021-2024 | Alunbrig, Ninlaro |
| Insmed, INC. | $81.68 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $71.80 | 2019 | |
| Esperion Therapeutics, INC. | $66.62 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $65.75 | 2023 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $59.48 | 2019-2023 | Imbruvica |
| Agios Pharmaceuticals, INC. | $51.08 | 2025 | Pyrukynd |
| Corium, LLC | $49.07 | 2023 | Adlarity |
| Ge Healthcare | $47.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $46.89 | 2019 | |
| G1 Therapeutics, INC. | $46.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.58 | 2020-2021 | |
| Kyowa Kirin, INC. | $37.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.04 | 2022 | |
| Medicomp INC | $26.72 | 2021 | |
| Intercept Pharmaceuticals, INC. | $24.81 | 2020 | |
| Mannkind Corporation | $24.21 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $23.66 | 2022 | |
| Ibsa Pharma INC. | $23.07 | 2023 | Tirosint, Licart |
| Tempus Ai, INC | $22.48 | 2024 | Xt Cdx |
| Recordati_rare_diseases_inc. | $22.04 | 2023 | Sylvant |
| Verastem, INC. | $17.68 | 2019 | |
| Epizyme, INC. | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunhee Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.